Zecuity Approval History
FDA Approved: Yes (Discontinued) (First approved January 17, 2013)
Brand name: Zecuity
Generic name: sumatriptan
Dosage form: Transdermal Patch
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Migraine
Marketing Status: Discontinued
Zecuity (sumatriptan iontophoretic transdermal system) is a serotonin (5HT) 1b/1d receptor agonist (triptan) indicated for the acute treatment of migraine.
Development History and FDA Approval Process for Zecuity
|Jan 18, 2013||NuPathe's Zecuity Approved by the FDA for the Acute Treatment of Migraine|
|Aug 30, 2011||FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.